Presented by Kenneth Offit, MD, MPH, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, New York.
J Natl Compr Canc Netw. 2017 May;15(5S):741-743. doi: 10.6004/jnccn.2017.0089.
Multigene testing is a complicated area, with advantages and disadvantages of testing for hereditary cancer syndromes. Currently, NCCN does not endorse routing multiplex testing outside of a research setting, and/or intensive genetic counseling regarding risks and benefits. The 2017 NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian and Colorectal provide suggestions for mutation carriers identified by panel tests.
多基因检测是一个复杂的领域，具有遗传性癌症综合征检测的优势和劣势。目前，NCCN 不支持在研究环境之外或/和关于风险和益处的强化遗传咨询之外进行常规的多重检测。2017 年 NCCN 肿瘤学遗传/家族性高风险评估临床实践指南：乳腺和卵巢和结直肠为通过面板检测确定的突变携带者提供了建议。
